0.00
price down icon100.00%   -8.16
after-market After Hours: 8.02 8.02 +
loading
Regulus Therapeutics Inc stock is traded at $0.00, with a volume of 0. It is down -100.00% in the last 24 hours and down -100.00% over the past month. Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
See More
Previous Close:
$8.16
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$564.26M
Revenue:
-
Net Income/Loss:
$-30.04M
P/E Ratio:
0.00
EPS:
-1.58
Net Cash Flow:
$-27.38M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
Value
$0.00
$0.00
1-Week Range:
Value
$0.00
$0.00
52-Week Range:
Value
$0.00
$8.345

Regulus Therapeutics Inc Stock (RGLS) Company Profile

Name
Name
Regulus Therapeutics Inc
Name
Phone
858-202-6300
Name
Address
4224 CAMPUS POINT COURT, SAN DIEGO, CA
Name
Employee
34
Name
Twitter
@regulusrx
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
RGLS's Discussions on Twitter

Compare RGLS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
RGLS
Regulus Therapeutics Inc
0.00 564.26M 0 -30.04M -27.38M -1.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.16 120.29B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
554.58 60.26B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
339.80 43.10B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
598.89 36.65B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.94 33.09B 3.81B -644.79M -669.77M -6.24

Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-27-25 Upgrade Wells Fargo Equal Weight → Overweight
Aug-02-24 Initiated Oppenheimer Outperform
Mar-18-24 Initiated Leerink Partners Outperform
Mar-28-18 Initiated B. Riley FBR, Inc. Neutral
Jan-05-18 Initiated Leerink Partners Outperform
Jun-13-17 Reiterated Chardan Capital Markets Buy
Mar-06-17 Reiterated Wedbush Outperform
Jan-30-17 Downgrade Needham Buy → Hold
Jan-30-17 Downgrade Wells Fargo Outperform → Market Perform
Dec-07-16 Reiterated Chardan Capital Markets Buy
Nov-02-16 Reiterated Needham Buy
Jul-25-16 Reiterated Chardan Capital Markets Buy
Jun-28-16 Reiterated Chardan Capital Markets Buy
Jun-28-16 Reiterated FBR Capital Outperform
Jun-28-16 Reiterated Needham Buy
Jun-07-16 Reiterated Chardan Capital Markets Buy
Apr-13-16 Initiated Chardan Capital Markets Buy
Dec-04-15 Initiated Wells Fargo Outperform
Jun-09-15 Initiated Guggenheim Buy
Apr-21-15 Resumed FBR Capital Outperform
Nov-24-14 Initiated Deutsche Bank Buy
Aug-07-14 Reiterated FBR Capital Outperform
Aug-14-13 Reiterated Needham Buy
View All

Regulus Therapeutics Inc Stock (RGLS) Latest News

pulisher
Jul 29, 2025

Reversal Traders Monitor Regulus Therapeutics Inc. for EntryShort Term Buy Zone Stock Alerts Signal Entry - beatles.ru

Jul 29, 2025
pulisher
Jul 28, 2025

What is the dividend policy of Regulus Therapeutics Inc. stockDynamic investment growth - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What are the latest earnings results for Regulus Therapeutics Inc.Superior stock selection - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What is Regulus Therapeutics Inc. company’s growth strategyAchieve breakthrough profits with smart strategies - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How does Regulus Therapeutics Inc. compare to its industry peersOutstanding risk-reward balance - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Does Regulus Therapeutics Inc. stock perform well during market downturnsConsistent wealth multiplication - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How volatile is Regulus Therapeutics Inc. stock compared to the marketFree Consultation - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

When is Regulus Therapeutics Inc. stock expected to show significant growthUnlock daily market insights for better trades - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What are analysts’ price targets for Regulus Therapeutics Inc. in the next 12 monthsGet professional advice for market timing - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Is it the right time to buy Regulus Therapeutics Inc. stockUnlock powerful portfolio optimization tools - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 25, 2025

What analysts say about Regulus Therapeutics Inc. stockFree Market Volatility Navigation Tips - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

Is Regulus Therapeutics Inc. a good long term investmentTriple-digit growth rates - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

What drives Regulus Therapeutics Inc. stock priceHigh-yield trading alerts - Autocar Professional

Jul 24, 2025
pulisher
Jul 23, 2025

Regulus Therapeutics Inc. Stock Analysis and ForecastConsistently exceptional gains - jammulinksnews.com

Jul 23, 2025

Regulus Therapeutics Inc Stock (RGLS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$77.55
price up icon 0.23%
$37.12
price down icon 0.40%
$105.18
price up icon 0.17%
$26.66
price down icon 0.30%
$110.05
price down icon 1.28%
biotechnology ONC
$299.94
price down icon 1.90%
Cap:     |  Volume (24h):